Floatz Rating
B61/100
Confidence
Indicative
Sponsor
Samsung Medical Center
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01823068CT.gov Vandetanib in Advanced NSCLC With RET Rearrangement | — | Completed | — | — | — |
NCT02117167CT.gov SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients | — | Completed | — | — | — |
NCT01586624CT.gov A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1) | — | Completed | — | — | — |
NCT01004419CT.gov Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT00807170CT.gov Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases | — | Terminated | — | — | — |
NCT00745732CT.gov Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00777179CT.gov Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy | — | Completed | — | — | — |
NCT00753714CT.gov Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine | — | Completed | — | — | — |
NCT00687297CT.gov Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00418886CT.gov Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients | — | Completed | — | — | — |
Show 9 more trialsShow fewer
NCT00404924CT.gov ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures | — | Completed | — | — | — |
NCT00496275CT.gov Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC | — | Completed | — | — | — |
NCT00364351CT.gov Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy | — | Completed | — | — | — |
NCT00312377CT.gov ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00506051CT.gov ZD6474(Vandetanib) + Alimta Combo Study | — | Completed | — | — | — |
NCT00252746CT.gov ZD6474 Phase IIa Dose Finding Multicentre Study | — | Completed | — | — | — |
NCT00071188CT.gov ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00059722CT.gov This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC. | — | Completed | — | — | — |
NCT00047840CT.gov This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer. | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Vandetanib (this asset) | Samsung Medical Center | P3 | B · 61 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Vandetanib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Gliosarcoma | — | P2 | B · 63 |
| Metastatic Neoplasm | — | P2 | B · 63 |
| Lung Cancer | — | P3 | B · 59 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Vandetanib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vandetanib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →